The global intravascular imaging market size is likely to be valued at US$459.0 million in 2026 and is expected to reach US$690.2 million by 2033, growing at a CAGR of 6.0% during the forecast period from 2026 to 2033, driven by the rising global burden of cardiovascular disease, growing adoption of image-guided interventional cardiology procedures, continuous advancement in intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging technology, and clinical evidence supporting intravascular imaging-guided percutaneous coronary intervention (PCI) outcomes improvement over angiography-guided procedures alone.

Driver - Rising Cardiovascular Disease Burden and Growing PCI Procedure Volumes

The rising global burden of coronary artery disease is a major driver of the intravascular imaging market. According to the WHO, coronary artery disease is the leading cause of death worldwide and accounts for the majority of cardiovascular disease-related deaths. The increasing disease burden is expanding the number of percutaneous coronary intervention (PCI) procedures performed each year. This is creating sustained demand for intravascular imaging systems used to optimize coronary stent placement. Global PCI procedure volumes have increased steadily over the past decade. Growth is supported by aging populations with a higher prevalence of atherosclerotic disease. Wider adoption of cardiac CT angiography and stress imaging is improving the detection of coronary artery disease. Expanding access to interventional cardiology services is also contributing to market growth. In Asia Pacific and other emerging markets, significant investments in cardiac catheterization laboratory infrastructure have further increased PCI procedure volumes.

According to the World Health Organization (WHO), cardiovascular diseases caused 19.8 million deaths globally in 2022, accounting for approximately 32% of all deaths worldwide. Additionally, 85% of these deaths were due to heart attacks and strokes, highlighting the growing need for coronary revascularization procedures such as PCI. Updated ACC/AHA and ESC guidelines increasingly recommend intravascular imaging (IVUS and OCT) during PCI, particularly for complex coronary lesions such as left main disease, bifurcations, long lesions, and calcified stenoses. These stronger recommendations are accelerating physician adoption and driving investment in intravascular imaging systems across cardiac catheterization laboratories.

Restraint - Operator Training Requirements and Learning Curve Adoption Constraints

Effective intravascular imaging interpretation requires specialized expertise in cross-sectional coronary image analysis, IVUS and OCT artifact recognition, plaque characterization, and stent optimization assessment. The resulting procedural learning curve can limit broader adoption among interventional cardiologists who lack dedicated training and experience in intravascular imaging.

Intravascular imaging adds extra time to standard PCI procedures. Catheter setup, image acquisition, interpretation, and stent optimization typically increase procedure time by 10–20 minutes. The additional time creates workflow efficiency challenges for high-volume catheterization laboratories. These facilities often operate under tight procedure scheduling constraints. As a result, longer procedure times can slow the adoption of intravascular imaging systems. Technology innovations are helping overcome this challenge. Automated pullback systems, rapid image analysis algorithms, and streamlined workflow designs are reducing procedure time and improving efficiency.

Opportunity - OCT Adoption Expansion and Combined IVUS-NIRS Platform Growth

Optical coherence tomography (OCT) is gaining wider clinical adoption for PCI guidance. Its growth is driven by superior image resolution compared with intravascular ultrasound (IVUS). OCT enables more precise stent sizing during PCI procedures. It also helps confirm complete stent strut apposition with greater accuracy. OCT also supports the assessment of thin-cap fibroatheroma, improving plaque vulnerability evaluation. These advantages are creating significant growth opportunities for OCT imaging system manufacturers. Revenue from OCT consoles and catheters is growing faster than the more mature IVUS segment.

This trend reflects the increasing shift of intravascular imaging-guided PCI procedures from IVUS to OCT guidance. Combined IVUS-NIRS (near-infrared spectroscopy) imaging platforms are expanding the capabilities of intravascular imaging. Systems such as Infraredx's TVC Imaging System and InfraReDx LipiScan integrate IVUS with NIRS technology. These platforms simultaneously detect lipid-rich coronary plaques while providing conventional IVUS anatomical imaging. This combination offers complementary diagnostic information during coronary interventions. It helps identify high-risk atherosclerotic plaques beyond the target lesion selected for stent placement. The additional clinical information can support preventive treatment decisions. It also improves patient risk stratification for future cardiovascular events.

Product Type Insights

Instruments are projected to account for 72% of the market revenue in 2026, driven by the high value of IVUS and OCT imaging systems, an expanding installed base in catheterization laboratories, and strong recurring demand for high-priced single-use imaging catheters. Boston Scientific Corporation, which markets the OPTICROSS™ HD Coronary Imaging Catheter and POLARIS™ Multi-Modality Guidance System for IVUS-guided PCI procedures.

Software is likely to be the fastest-growing product segment, driven by increasing adoption of AI-powered image analysis, plaque characterization, stent optimization, angiographic co-registration, and quantitative reporting solutions that enhance clinical decision-making and generate recurring software revenue. Abbott’s Ultreon™ Software uses AI-powered OCT imaging to provide plaque assessment, angiographic co-registration, vessel sizing, and stent optimization guidance during PCI procedures.

Modality Insights

Trolley-mounted systems are expected to hold around 68% of the market share in 2026, driven by their widespread use in cardiac catheterization laboratories, advanced imaging capabilities, integrated workflow support, and comprehensive analysis features for interventional cardiology procedures. Philips and its IntraSight Interventional Applications Platform, a trolley-mounted IVUS imaging system widely used in cardiac catheterization laboratories.

Handheld intravascular imaging systems are estimated to be the fastest-growing modality segment, supported by their portability, lower cost, and compact design, which support adoption in smaller catheterization laboratories, hybrid operating rooms, and resource-constrained healthcare settings. Philips and its IntraSight Mobile platform, a compact IVUS imaging system designed for hospitals, office-based labs, and ambulatory surgery centers.

End-user Insights

Hospitals are expected to dominate the command for 65% of total revenue in 2026, fueled by the large volume of PCI procedures performed in hospital-based cardiac catheterization laboratories and the widespread use of IVUS and OCT imaging in both academic and community healthcare settings. Abbott and its OPTIS™ Next Imaging System with Ultreon™ Software, which is widely used in hospital-based cardiac catheterization laboratories for OCT-guided PCI procedures.

Ambulatory Surgical Centers (ASCs) are likely to be the fastest-growing end-user segment, propelled by the increasing shift of lower-complexity PCI procedures to outpatient settings and rising demand for compact, cost-effective intravascular imaging systems. Terumo Interventional Systems’ LUNAWAVE™ OFDI System provides a compact intravascular imaging platform with advanced imaging capabilities and streamlined workflow, making it well-suited for smaller and resource-constrained catheterization laboratories.

North America Intravascular Imaging Market Trends

North America is projected to dominate the market, accounting for approximately 41% of global revenue in 2026. The region's leadership is driven by the extensive network of cardiac catheterization laboratories in the U.S., strong ACC/AHA clinical guideline support for intravascular imaging-guided PCI in complex coronary lesions, broad insurance reimbursement for intravascular imaging-guided procedures, and the presence of leading industry innovators, including Boston Scientific.

U.S Intravascular Imaging Market Insights

The U.S. is expected to remain the world's largest intravascular imaging market, accounting for approximately 85% of North America's market share in 2026. Its leadership is driven by the country's high burden of coronary artery disease, the large volume of PCI procedures performed annually across more than 2,000 cardiac catheterization laboratories, and ACC/AHA clinical practice guidelines and Appropriate Use Criteria that support the use of intravascular imaging for complex coronary interventions.

Canada Intravascular Imaging Market Insights

Canada is expected to account for approximately 15% of the North American intravascular imaging market in 2026. Market growth is supported by the country's provincial healthcare system, with cardiac catheterization services concentrated at major regional cardiac centers such as Toronto General Hospital, Vancouver General Hospital, and CHUM in Montreal, all of which have established IVUS and OCT imaging programs within their interventional cardiology services.

Europe Intravascular Imaging Market Trends

Europe is anticipated to be the second-largest regional intravascular imaging market, accounting for approximately 26% of global revenue in 2026. Market growth is supported by the European Society of Cardiology's clinical guidelines recommending IVUS-guided PCI for selected complex coronary lesions, well-established cardiac catheterization laboratory infrastructure across major European healthcare systems, and the region's strong interventional cardiology research community, which has played a significant role in advancing landmark clinical trials on intravascular imaging-guided PCI.

Germany Intravascular Imaging Market Trends

Germany is expected to lead the European intravascular imaging market, accounting for more than 35% of the regional market share in 2026. Its leadership is driven by an extensive network of cardiac catheterization laboratories across well-established university hospitals and specialized cardiac centers, strong adoption of European Society of Cardiology (ESC) guidelines supporting intravascular imaging in complex PCI procedures, and the presence of Siemens Healthineers, a global leader in cardiovascular imaging technologies headquartered in the country.

U.K. Intravascular Imaging Market Trends

The U.K. is expected to account for approximately 20% of the European intravascular imaging market in 2026. Market growth is supported by NHS England commissioning policies, NICE technology assessments, and British Cardiovascular Intervention Society (BCIS) clinical guidelines promoting the appropriate use of intravascular imaging. Adoption is further strengthened by leading cardiac centers, including Royal Brompton Hospital, Leeds General Infirmary, and Imperial College Healthcare NHS Trust, which actively utilize IVUS and OCT technologies and participate in intravascular imaging-guided PCI research.

Asia Pacific Intravascular Imaging Market Trends

Asia Pacific is projected to be the fastest-growing regional intravascular imaging market during the forecast period. Growth is driven by expanding investments in interventional cardiology infrastructure, the rising prevalence of coronary artery disease across aging and urbanizing populations, high adoption of IVUS and OCT in Japan, and increasing implementation of intravascular imaging-guided PCI across major healthcare systems in China, South Korea, and India.

Japan Intravascular Imaging Market Trends

Japan is expected to lead the Asia Pacific intravascular imaging market, accounting for approximately 40% of the regional market share in 2026. The country has one of the highest adoption rates of intravascular imaging during PCI procedures, supported by its long-established use of IVUS in routine clinical practice. Japan has also played a pioneering role in advancing intravascular imaging research, while its emphasis on precision-guided coronary interventions has made IVUS and OCT integral components of PCI procedures rather than technologies reserved solely for complex lesions.

China Intravascular Imaging Market Trends

China is expected to be the fastest-growing intravascular imaging market in the Asia Pacific region, accounting for approximately 25% of the regional market share in 2026. Market growth is driven by the rapid expansion of cardiac catheterization laboratories, continued investment in cardiac care infrastructure at major tertiary hospitals, and the rising burden of coronary artery disease associated with urbanization, changing lifestyles, and an aging population. Adoption of intravascular imaging-guided PCI is also increasing as Chinese interventional cardiologists align more closely with international clinical guideline recommendations.

The global intravascular imaging market is moderately concentrated, with competition led by a handful of established cardiovascular medical device companies offering comprehensive IVUS and OCT portfolios. The market also includes diversified imaging technology providers with broader cardiovascular product offerings, as well as emerging manufacturers in the Asia Pacific region focused on cost-effective intravascular imaging solutions.

Boston Scientific Corporation is a leading player in the IVUS segment, supported by its OptiCross™ and POLARIS™ intravascular ultrasound portfolio, extensive interventional cardiology sales network, and strong clinical support programs across catheterization laboratories in North America, Europe, and Asia Pacific. Abbott maintains a strong position in the OCT segment through its OPTIS™ Integrated System, which combines optical coherence tomography with angiographic co-registration to support image-guided PCI. The company competes closely with Philips, whose integrated IVUS platform continues to strengthen its presence in the growing market for intravascular imaging-guided complex coronary interventions.

Key Industry Developments:

• In April 2026, Conavi Medical Corp. received FDA 510(k) clearance for its next-generation hybrid imaging system designed to support minimally invasive cardiovascular procedures. Following the approval, the company announced plans to launch a limited market release across selected U.S. medical centers during the second half of 2026.
• In March 2026, Boston Scientific Corporation launched the iCross™ Coronary Imaging Catheter to enhance the deliverability and performance of its iLab® Intravascular Ultrasound (IVUS) Imaging System. The company introduced the catheter to provide physicians with improved access and detailed visualization of coronary arteries during cardiovascular interventions and made the product immediately available.